Analysis of iodine-125 interstitial therapy in the treatment of localized carcinoma of the prostate |
| |
Authors: | L G Gomella S M Steinberg M F Ellison W W Reeves R C Flanigan J W McRoberts |
| |
Affiliation: | Department of Surgery, University of Kentucky Medical Center, Lexington. |
| |
Abstract: | Definitive treatment of localized carcinoma of the prostate has included radical surgery, external beam radiation therapy, and interstitial radiation therapy. The interstitial agent most commonly used is Iodine-125. Forty-eight patients were treated with interstitial radiation therapy using Iodine-125 implants with a median follow-up of 55 months. Forty-three percent of the evaluable patients had progressive disease with approximately 50% progressing at 5 years by Kaplan-Meier analysis. Overall actuarial survival in the group was 80% at 5 years. This and several other studies suggest that control of prostate cancer with Iodine-125 seeds may be suboptimal as compared with other treatment modalities, especially the radical retropubic prostatectomy. Analysis of treatment parameters is presented along with a discussion of the current status and future prospects for treatment of localized carcinoma of the prostate with interstitial radiation therapy. |
| |
Keywords: | radical retropubic prostatectomy progression rate survival radiation therapy prostate cancer |
|